2015 Fiscal Year Final Research Report
A novel anti tumor immunotherapy to eliminate circulating tumor cells of SCLC
| Project/Area Number |
26670415
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Saitama Medical University (2015)
Niigata University (2014) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Tsuchida Masanori 新潟大学, 医学部, 教授 (60293221)
Umezu Hajime 新潟大学, 医歯学総合病院, 准教授 (50251799)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Keywords | 小細胞肺癌 / 循環腫瘍細胞 / 癌幹細胞 / DDX3X |
|---|
| Outline of Final Research Achievements |
We have reported that cancer cells expressing DDX3X possessed ability to proliferate in an anchorage independent manner, and acquired cancer stem cell (CSC)-like characteristics, such as high migration and proliferation activity.
In this study, it was elucidated that cancer cells circulating in peripheral blood of extended stage disease (ED) small cell lung cancer (SCLC) patients expressed DDX3X, but that those of limited stage disease (LD) SCLC did not. On the other hand, T-lymphocytes in peripheral blood of LD-SCLC patients recognized DDX3X and secreted IFNγ, but that T-lymphocytes of ED-SCLC patients could not. In conclusion, it is likely that antitumor T-lymphocytes recognizing DDX3X eliminated DDX3X-positive CSC-like circulating cancer cells and prevented distant metastases.
|
| Free Research Field |
呼吸器内科
|
